Integra LifeSciences Holdings Corporation (IART) Trend Exposure

Source: SEC EDGAR filings · figures as of 2026-09-30 · read by EquiReason

IARTIntegra LifeSciences Holdings CorporationFollow IART — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 926.6M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 24 Feb, in 123 days

06Trend linkNo board trend is attached — the score stands on company evidence alone.

Measured evidence ladder Analyst

The measured evidence ladder is in Analyst. 18 behind this lock.

Try it free for 7 days

Transmission map Analyst

The transmission map is in Analyst.

Try it free for 7 days

Measured trend shares Analyst

Measured trend shares are in Analyst.

Try it free for 7 days

Rank among beneficiaries Analyst

Rank among beneficiaries is in Analyst. 203 behind this lock.

Try it free for 7 days

SEC validation detail Analyst

SEC validation detail is in Analyst.

Try it free for 7 days

Every figure on this page comes from Integra LifeSciences Holdings Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.